MedImmune Deal Exposes Early-Stage University of California, San Francisco (UCSF) Drugs

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MedImmune is looking to UCSF researchers to feed its drug pipeline. In a three-year deal with the University of California, San Francisco's Clinical and Translational Science Institute, the biologics R&D unit of AstraZeneca hopes to spot potential early-research drugs for a wide-range of diseases, including cancer, heart disease, metabolic diseases, neuroscience and infectious diseases. Financial terms of the deal were not disclosed.

Help employers find you! Check out all the jobs and post your resume.

Back to news